Navigation Links
Local therapy followed by treatment with EGFR TKI is well tolerated
Date:2/22/2013

DENVER Local therapy is not commonly utilized in metastatic lung cancer. Researchers at Memorial Sloan-Kettering Cancer Center investigated the efficacy of local therapy with continued EGFR TKI therapy specifically in patients with acquired resistance to EGFR TKIs. A recent study published in the March 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, found that EGFR- mutant lung cancers with acquired resistance to EGFR TKI therapy are amenable to local therapy to treat oligometastatic disease when used in conjunction with continued EGFR inhibition.

Eighteen patients were identified who received elective local therapy (surgical resection, radiofrequency ablation or radiation). Local therapy was well-tolerated, with 85 percent of the patients restarting TKI therapy within one month of local therapy. Local therapy with surgery, radiation, or radiofrequency ablation in selected patients is associated with a median overall survival of 41 months, a median time to progression of 10 months, and a median time to next systemic therapy of 22 months.

Researchers report that, "these remarkable outcomes in patients with EGFR mutant lung cancer are likely a result of multiple factors including the unique clinical course of this disease, patient selection, continued benefits of the TKI even after progression, and potential benefits of local therapy."

They also say, "While the patients reported here had long median overall survivals and delayted time to disease progression, there was a wide range of outcomes. Outcomes appeared to be best when the site of local therapy was the only known site of disease." Their experience suggests, "local therapy should be considered for patients with oligometastatic lung cancer with acquired resistance to EGFR TKI."


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related biology news :

1. Chinese scientists discover evidence of giant pandas population history and local adaptation
2. Maple syrup, moose, and the local impacts of climate change
3. Greater effort needed to move local, fresh foods beyond privileged consumers
4. Global economic pressures trickle down to local landscape change, altering disease risk
5. In Fiji, marine protection gets local boost
6. Long-distance distress signal from periphery of injured nerve cells begins with locally made protein
7. First paternity study of southern right whales finds local fathers most successful
8. Managing biodiversity data from local government
9. New therapy for heart failure may enhance bodys stem cell response at cardiovascular injury site
10. Cell therapy a little more concrete thanks to VIB research
11. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... a key source of water for millions of people in ... climate changes as expected and future water usage is not ... of Oceanography, UC San Diego. Without Lake ... no buffer to sustain the population of the Southwest through ...
... Feb. 11 Most fashion consumers consider,custom-made jeans ... lottery,winners. But Intellifit, a leader in proprietary apparel ... perception., This week, the company will begin ... company retail store outside of Philadelphia. Using Intellifit,technology, ...
... the Moores Cancer Center at University of California, San Diego ... were treated with a gene therapy protocol began making antibodies ... be published on line the week of February 11-15 in ... of Science. Researchers led by Thomas J. Kipps, M.D., ...
Cached Biology News:Lake Mead could be dry by 2021 2Lake Mead could be dry by 2021 3Intellifit(R) Offers Custom-Made Jeans with a High-Tech Twist 2Gene therapy protocol at UCSD activates immune system in patients with leukemia 2
(Date:5/4/2015)... FRANCISCO, Calif. , May 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... announced today the completion of its merger with ... In conjunction with the closing of the merger, ... a combination of new investors and all current ...
(Date:5/4/2015)... BOSTON , May 4, 2015 ... development of novel therapies for neurological and neuropsychiatric ... has initiated dosing of Alzheimer,s patients in a ... candidate, GC021109, a compound developed as a potential ... disease is innovative in that it both promotes ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), ... the appointment of Dr. Roger J Garceau, to ... biotech companies in matters including corporate development and ... and adds significant regulatory expertise as Fluorinov transitions ... brings 30 years of pharmaceutical development experience to ...
(Date:5/4/2015)... Genedata, a leading provider of advanced ... research, today announced the release of Genedata ... enterprise solution for biologics R&D. This first-in-class workflow ... and development of novel biotherapeutics. Version 5.0 enables ... optimization and developability requirements. Genedata will present highlights ...
Breaking Biology Technology:Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4
... New Launches Should Contribute Significantly in Second Half, ... PRX ) today announced results for the,second quarter ended ... For the second quarter ended June 28, 2008, Par ... $20.1 million, or $0.60 per diluted,share. This is compared with ...
... ITMN ) today announced that Daniel G. Welch, ... Canaccord Adams 28th Annual,Global Growth Conference in Boston on ... access a live audio webcast of the presentation, investors ... relations page of InterMune,s,corporate website at http://www.intermune.com . ...
... YORK, Aug. 7 Microbes, Inc. today announced that ... all of its outstanding,Class B Common Stock Purchase Warrants, ... 2 until 12:00 midnight, New York City time, on,Friday, ... at 12:00,midnight, New York City time, on August 7, ...
Cached Biology Technology:Par Pharmaceutical Reports Second Quarter 2008 Results 2Par Pharmaceutical Reports Second Quarter 2008 Results 3Par Pharmaceutical Reports Second Quarter 2008 Results 4Par Pharmaceutical Reports Second Quarter 2008 Results 5Par Pharmaceutical Reports Second Quarter 2008 Results 6Par Pharmaceutical Reports Second Quarter 2008 Results 7Par Pharmaceutical Reports Second Quarter 2008 Results 8